Latham

Researchers are evaluating the effectiveness and safety of Corabotase IPN10200 in adults with moderate to severe glabellar lines, which are wrinkle-like lines between the eyebrows that may affect appearance and confidence. This Phase III study compares a single dose of Corabotase to a placebo in a double-blind phase, followed by an open-label phase to assess repeat doses over time. Participants will receive injections of Corabotase or placebo into selected facial muscles. The study includes a screening period of up to 20 days, a treatment period with up to four treatment cycles where participants may receive Corabotase or placebo in the double-blind phase and Corabotase in the open-label phase, and a follow-up period lasting 24 weeks after the last injection. Multiple visits occur during the first month of treatment, followed by monthly visits. During the study, participants will have health assessments including blood tests, physical exams, ECGs, questionnaires, and diaries. Researchers will measure treatment response at week 4 and monitor safety and satisfaction through week 104. Total participation lasts up to 107 weeks, and participants may withdraw at any time.

Researchers are investigating the safety and effectiveness of NOA VOLUME, a crosslinked Hyaluronic Acid injectable gel with lidocaine, designed to improve mid-face volume in adults. This study compares NOA VOLUME with another injectable gel, JUVDERM VOLUMA XC, in adults seeking mid-face volume enhancement. The trial enrolls around 231 participants and aims to address facial volume loss caused by aging factors like collagen and elastin reduction. Participants are randomly assigned to receive either NOA VOLUME or VOLUMA XC injections in the cheek area on Day 1. They may receive optional touch-up treatments on Day 31 and Month 18. The study includes two cohorts, with treatments administered under a quadruple-masked design to maintain objectivity. The follow-up period extends up to 31 months to monitor long-term outcomes. Throughout the study, participants will be assessed on their mid-face volume improvement using investigator and participant evaluations, including the Mid-Face Volume Deficit Scale and Global Aesthetic Improvement Scale. Safety is monitored by recording adverse events over the entire follow-up period. Participants will have scheduled visits for injections and evaluations, with the primary effectiveness measured at Month 6 and safety tracked up to Month 31.